Antiviral Agents: A New Beginning

  • George J. Galasso
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 143)


Review of the statements I made at the last meeting four years ago showed that the major change that has occurred since then is not so much one of increased knowledge on antiviral drugs, but more importantly, one of attitude. The prevailing skepticism of the past has given way to optimism and determination. This determination is partially due to recent successes in the field, but more likely results from the acquired immunodeficiency syndrome (AIDS) epidemic.


Human Immunodeficiency Virus Respiratory Syncytial Virus Antiviral Drug Antiviral Agent Genital Herpes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. J. Galasso, Antiviral agents: Why not a “penicillin” for antiviral infections?, in: “Targets for the Design of Antiviral Agents?,” E. DeClercq and R. T. Walker, eds., Plenum Press, New York (1984).Google Scholar
  2. 2.
    T. J. Smith, M. J. Kremer, M. Luo, G. Vriend, E. Arnold, G. Kamer, M. G. Rossmann, M. A. McKinlay, G. D. Diana and M. J. Otto, The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating, Science 233:1286–1293 (1986).PubMedCrossRefGoogle Scholar
  3. 3.
    D. H. Shepp, P. S. Dandliker and J. D. Meyers, Treatment of varicella-zoster virus infection in severely immunocompromised patients: A randomized comparison of acyclovir and vidarabine, NEJM 314:208–212 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    J. L. Vilde, F. Bricaire, C. Leport, M. Renaudie and F. Brunvezinet, Comparative trial of acyclovir and vidarabine in disseminated varicella-zoster virus infections in immunocompromised patients, J. Med. Virol. 20:127–134 (1986).PubMedCrossRefGoogle Scholar
  5. 5.
    S. Feldman, P. K. Robertson, L. Lott and D. Thornton, Neurotoxicity due to adenine arabinoside therapy during varicella-zoster virus infections in immunocompromised children, JID 154:889–893 (1986).PubMedCrossRefGoogle Scholar
  6. 6.
    B. Leyland-Jones, H. Donnelly, S. Goshen, P. Myskowski, A. L. Donner, M. Fanucchi, J. Fox and the Memorial Sloan-Kettering Antiviral Working Group, 2′-Fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: Efficacy in immunosuppressed individuals with herpes zoster, JID 154:430–436 (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    R. J. Whitley, C. A. Alford, Jr., M S. Hirsch, R. T. Schooley, J. P. Luby, F. Y. Aoki, D. Hanley, A. J. Nahmias and S-J Soong, Vidarabine vs. acyclovir therapy in herpes simplex encephalitis, NEJM 314:144–149 (1986).PubMedCrossRefGoogle Scholar
  8. 8.
    R. J. Whitley, A. J. Nahmias, S-J Soong, G. J. Galasso, C. L. Fleming and C. A. Alford, Jr., Vidarabine therapy of neonatal herpes simplex virus infection, J. Ped. 66:495–501 (1980).Google Scholar
  9. 9.
    R. J. Whitley, A. Arvin, L. Corey, D. Powell, S. Plotkin, S. Starr, C. A. Alford, Jr., J. Connor, A. J. Nahmias, S-J Soong and the NIAID Collaborative Study Group, Vidarabine versus acyclovir therapy of neonatal herpes simplex virus infection, Society for Pediatric Research, Abstract #987, Washington, D.C. (1986).Google Scholar
  10. 10.
    S. E. Straus, H. E. Takiff, M. Scidlin, S. Bachrach, L. Linninger, J. J. DiGiovanna, K. A. Western, H. A. Smith, S. Nusinoff-Lehrman, T. Creagh-Kirk and D. W. Alling, Suppression of frequently recurring genital herpes: A placebo controlled double-blind trial of oral acyclovir, NEJM 310:1545–1550 (1984).PubMedCrossRefGoogle Scholar
  11. 11.
    J. M. Douglas, C. Critchlow, J. Benedetti, G. J. Mertz, J. D. Conner, M. A. Hintz, A. Fahnlander, M. Remington, C. Winter and L. Corey, A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection, NEJM 310:1551–1556 (1984).PubMedCrossRefGoogle Scholar
  12. 12.
    S. E. Straus, M. Scidlin, H. E. Takiff, J. F. Rooney, S. Nusinoff-Lehrman, S. Bachrach, J. M. Felser, J. J. DiGiovanni, G. J. Grimes, Jr., H. Krakauer, C. Hallahan and D. Alling, Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes, Antiviral Res. 6:151–159 (1986).PubMedCrossRefGoogle Scholar
  13. 13.
    J. L. Drucker, L. G. Davies, and the Herpes Collaborative Group, Abstr., 2nd World Congress Sex. Transm. Dis., (1986).Google Scholar
  14. 14.
    D. H. Shepp, P. S. Dandliker, N. Flournoy and J. D. Meyers, Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation, J. Antimicrob. Chemother. 16:389–395 (1985).PubMedCrossRefGoogle Scholar
  15. 15.
    J. M. Douglas, Jr., F. N. Judson, M. J. Levin, J. A. Bosso, S. L. Spruance, J. M. Johnston, L. Corey, J. A. McMillan, L. B. Weiner and J. A. Frank, Jr., A placebo-controlled trial of topical 8% arildone cream early in recurrent genital herpes, Antimicrob. Ag. Chemother. 29:464–467 (1986).Google Scholar
  16. 16.
    S. L. Sacks, J. Portnoy, D. Lawee, W. Schlech III, F. Y. Aoki, D. L. Tyrrell, M. Poisson, C. Bright, J. Kaluski and the Canadian Cooperative Study Group, Clinical course of recurrent genital herpes and treatment with foscarnet cream: Results of a Canadian multicenter trial, JID 155:178–185 (1987).PubMedCrossRefGoogle Scholar
  17. 17.
    Collaborative DHPG Treatment Study Group, Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies, NEJM 314:801–805 (1986).CrossRefGoogle Scholar
  18. 18.
    O. L. Laskin, C. M. Stahl-Bayliss, C. M. Kaiman and L. R. Rosecan, Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS, JID 155:323–327 (1987).PubMedCrossRefGoogle Scholar
  19. 19.
    O. Ringden, H. Wilczek, B. Lonnqvist, G. Gahrton, B. Wahren and J. O. Lernestedt, Foscarnet for cytomegalovirus infections, Lancet 1:1503–1504 (1985).PubMedCrossRefGoogle Scholar
  20. 20.
    G. Klintmalm, B. Lonnqvist, B. Oberg, G. Gahrton, J. O. Lernestedt, G. Lundgren, O. Ringden, K. H. Robert, B. Wahren and C.G. Groth, Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients, Scand. J. Inf. Dis. 17:157–163 (1985).Google Scholar
  21. 21.
    H. A. Blacklock, P. Griffiths, P. Stirk and H. G. Prentice, Specific hyper-immune globulin for cytomegalovirus pneumonitis, Lancet 2:152–153 (1985).PubMedCrossRefGoogle Scholar
  22. 22.
    J. Rush and J. Mills, Effects of combinations of difluromethylornithine and 9[(1,3-dihydroxy-2-propoxy)methyl]-guanine (DHPG) on human cytomegalovirus, J. Med. Virol. 21:269–276 (1987).PubMedCrossRefGoogle Scholar
  23. 23.
    S. R. Turk, C. Shipman, Jr., R. Nassiri, G. Genzlinger, S. H. Krawczyk, L. B. Townsend and J. C. Drach, Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus, Antimicrob. Ag. Chemother. 31:544–550 (1987).Google Scholar
  24. 24.
    J. Andersson, S. Britton, I. Ernberg, U. Andersson, W. Henle, B. Skoldenberg and A. Tisell, Effect of acyclovir on infectious mononucleosis: A double-blind placebo-controlled study, JID 153:283–290 (1986).PubMedCrossRefGoogle Scholar
  25. 25.
    R. M. Douglas, B. W. Moore, H. B. Miles, L. M. Davies, N. M. H. Graham, P. Ryan, D. A. Worswick and J. K. Albrecht, Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting, NEJM 314:65–70 (1986).PubMedCrossRefGoogle Scholar
  26. 26.
    F. G. Hayden, J. K. Albrecht, D. L. Kaiser and J. M. Gwaltney, Jr., Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon, NEJM 314:71–75 (1986).PubMedCrossRefGoogle Scholar
  27. 27.
    L. C. Jennings and E. C. Dick, Transmission and control of rhinovirus colds, Eur. J. Epidemiol. (in press).Google Scholar
  28. 28.
    E. C. Dick, S. U. Hossain, K. A. Mink, C. K. Meschievitz, S. B. Schultz, W. J. Raynor and S. L. Inhorn, Interrruption of transmission of rhinovirus colds among human volunteers using virucidal paper handkerchiefs, JID 153:352–356 (1986).PubMedCrossRefGoogle Scholar
  29. 29.
    G. A. Eby, D. R. Davis and W. W. Halcomb, Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study, Antimicrob. Ag. Chemother. 25:20–24 (1984).Google Scholar
  30. 30.
    F. C. Geist, J. A. Bateman and F. G. Hayden, In vitro activity of zinc salts against human rhinoviruses, Antimicrob. Ag. Chemother. 31:622–624 (1987).Google Scholar
  31. 31.
    R. Dolin, R. C. Reichman, H. P. Madore, R. Maynard, P. N. Linton and J. Webber-Jones, A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection, NEJM 307:580–584 (1982).PubMedCrossRefGoogle Scholar
  32. 32.
    F. G. Hayden and A. S. Monto, Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults, Antimicrob. Ag. Chemother. 29:339–341 (1986).Google Scholar
  33. 33.
    J. Thompson, W. Fleet, E. Lawrence, E. Pierce, L. Morris and P. Wright, A comparison of acetaminophen and rimantadine in the treatment of influenza and infection in children, J. Med. Virol. 21:249–255 (1987).PubMedCrossRefGoogle Scholar
  34. 34.
    S. Z. Wilson, B. E. Gilbert, J. M. Quarles, V. Knight, H. W. McClung, R. V. Moore and R. B. Couch, Treatment of influenza A (H1N1) virus infection with ribavirin aerosol, Antimicrob. Ag. Chemother. 26:200–203 (1984).Google Scholar
  35. 35.
    H. W. McClung, V. Knight, B. E. Gilbert, S. Z. Wilson, J. M. Quarles and G. W. Divine, Ribavirin aerosol treatment of influenza B virus infection, JAMA 249:2671–2674 (1983).PubMedCrossRefGoogle Scholar
  36. 36.
    C. B. Hall, J. T. McBride, E. E. Walsh, D. M. Bell, C. L. Gala, S. Hildreth, L. G. TenEyck and W. J. Hall, Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection: A randomized double-blind study, NEJM 308:1443–1447 (1983).PubMedCrossRefGoogle Scholar
  37. 37.
    C. B. Hall, J. T. McBride, C. L. Gala, S. W. Hildreth and K. C. Schnabel, Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease, JAMA 254:3047–3051 (1985).PubMedCrossRefGoogle Scholar
  38. 38.
    C. B. Hall and J. T. McBride, Vapors, viruses and views, AJDC 140:331–332 (1986).PubMedGoogle Scholar
  39. 39.
    J. B. McCormick, I. J. King, P. A. Webb, K. M. Johnson, R. O’Sullivan, E. S. Smith, S. Trippel and T. C. Tong, A case control study of the clinical diagnosis and course of Lassa fever, JID 155:445–455 (1987).PubMedCrossRefGoogle Scholar
  40. 40.
    J. B. McCormick, I. J. King, P. A. Webb, C. L. Scribner, R. B. Craven, K. M. Johnson, L. H. Elliott and R. Belmont-Williams, Lassa Fever: Effective therapy with ribavirin, NEJM 314:20–26 (1986).PubMedCrossRefGoogle Scholar
  41. 41.
    J. I. Maiztegui, N. J. Fernandez and A. J. de Damilano, Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and late neurological syndrome, Lancet 2:1216–1217 (1979).PubMedCrossRefGoogle Scholar
  42. 42.
    H. B. Greenberg, R. B. Pollard, L. I. Lutwick, P. B. Gregory, W. S. Robinson and T. C. Merigan, Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis, NEJM 295:517–522 (1976).PubMedCrossRefGoogle Scholar
  43. 43.
    R. A. deMan, S. W. Schalm, R. A. Heytink, R. Charmuleau, H. Reesink, J. den Ouden, R. Grym, M. deJong, J. T. M. v.d. Heyden and F. J. W. ten Kate, Interferon plus descyclovir in chronic hepatitis B: Incidence of virus marker elimination and reactivation, J. Med. Virol. 21:120A (1987).Google Scholar
  44. 44.
    O. Yokosuka, M. Omata, F. Imazeki, K. Hirota, J. Mori, K. Uchiuma, Y. Ito and K. Okuda, Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B, Gastroenterology 89:246–251 (1985).PubMedGoogle Scholar
  45. 45.
    R. Perillo, F. Regenstein, M. Peters, C. Bodicky and C. Campbell, A randomized, controlled trial of prednisone withdrawal followed by recombinant alpha interferon (rIFN-∝ in the treatment of chronic hepatitis B, J. Med. Virol. 21:124A–125A (1987).Google Scholar
  46. 46.
    H. Mitsuya and S. Broder, Strategies for antiviral therapy in AIDS, Nature 325:773–778 (1987).PubMedCrossRefGoogle Scholar
  47. 47.
    R.B. Roberts, P.N.R. Haseltine, P.W.A. Mansell, G.M. Dickinson, J.M. Leedom and K.M. Johnson, Ribavirin delays progression of the lymphadenopathy syndrome to the acquired immune deficiency syndrome, Clin. Res. 35:616A (1987).Google Scholar
  48. 48.
    E. P. Gelman, O. T. Preble, R. Steis, H. C. Lane, A. H. Rook, M. Wesley, J. Jacob, A. Fauci, H. Masur and D. Longo, Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome: Clinical response and prognosis parameters, Am. J. Med. 78:737–741 (1985).CrossRefGoogle Scholar
  49. 49.
    K.L. Hartshorn, M.W. Vogt, T-C Chou, R.S. Blumberg, R. Byington, R.T. Schooley and M.S. Hirsch, Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and. recombinant alpha A interferon, Antimicrob. Ag. Chemother. 31:168–172 (1987).Google Scholar
  50. 50.
    L. Resnick, P. D. Markham, K. Veren, S. Z. Salahuddin and R. C. Gallo, In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin, JID 154:1027–1030 (1986).PubMedCrossRefGoogle Scholar
  51. 51.
    R.F. Schinazi, Drug combination for treatment of mice infected with acyclovir-resistant herpes simplex virus, Antimicrob. Ag. Chemother. 31:477–479 (1987).Google Scholar
  52. 52.
    M.W. Vogt, K.L. Hartshorn, P.A. Furman, T-C Chou, J.A. Fyfe, L.A. Coleman, C. Crumpacker, R.T. Schooley, S. Hirsch, Ribavirin antagonizes the effect of azidothymidine on HIV replication, Science 235:1376–1379 (1987).PubMedCrossRefGoogle Scholar
  53. 53.
    M.A. McKinlay and B.A. Steinberg, Oral efficacy of WIN 51711 in mice infected with human poliovirus, Antimicrob. Ag. Chemother. 29:30–32 (1986).Google Scholar
  54. 54.
    M.A. McKinlay, J.A. Frank, Jr., D.P. Benziger and B.A. Steinberg, Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice, JID 154:676–681 (1986).PubMedCrossRefGoogle Scholar
  55. 55.
    C.S. Crumpacker, L.E. Schnipper, S.I. Marlowe, P.N. Kowalsky, B.J. Hershey and M.S. Levin, Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir, NEJM 306:343–346 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • George J. Galasso
    • 1
  1. 1.National Institutes of HealthBethesdaUSA

Personalised recommendations